Vigil Neuroscience, Inc. (Nasdaq: VIGL), a clinical-stage biotechnology company committed to harnessing the power of microglia for the treatment of neurodegenerative diseases, today announced that ...

Iluzanebart, Vigil's lead clinical candidate, is a fully human monoclonal antibody agonist targeting human triggering receptor expressed on myeloid cells 2 (TREM2) in people with adult-onset ...

Iluzanebart, Vigil’s lead clinical candidate, is a fully human monoclonal antibody agonist targeting human triggering receptor expressed on myeloid cells 2 (TREM2) in people with adult-onset ...

Vigil Neuroscience, Inc., a clinical-stage biotechnology company listed on the Nasdaq under the symbol VIGL, recently unveiled promising results from its Phase 1 clinical trial for the experimental ...

Every year at our Vigil of All Saints, we meet people who say: “This is great! Why don’t we do this everywhere?” In fact, every year, we get inquiries from around the country asking us to ...

PUEBLO, Colo. – Colorado State University Pueblo has announced a five-year contract extension for head football coach Philip Vigil to continue to lead the ThunderWolves football program through ...